Monoclonal antibodyFDA-approvedSecond-line
Bevacizumab
How it works
Blocks the growth of new blood vessels that feed cancer cells, starving them of nutrients and oxygen.
Cancer types
Efficacy
Bevacizumab has been shown to improve progression-free survival in ovarian cancer patients.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Evaluating Pumitamig and Bevacizumab in Colorectal Cancer Treatment | Colorectal Cancer | phase-2 | — | Source → |
| Testing Olaparib for Ovarian Cancer Treatment | Ovarian Cancer | phase-3 | — | Source → |
| New Treatment Combination Tested for Lung Cancer Patients with Brain Metastases | Lung Cancer | phase-1 | — | Source → |
| Evaluating Treatment Options for Metastatic Colorectal Cancer | Colorectal Cancer | phase-3 | — | Source → |
| Bevacizumab Added to Chemotherapy May Improve Lung Cancer Progression-Free Survival | Lung Cancer | phase-3 | The hazard ratio for progression-free survival was 0.69 (95% CI 0.52-0.92) in favor of the bevacizumab group. | Source → |
| Testing IACS-6274 with or without Bevacizumab and Paclitaxel for Advanced Solid Tumors | Ovarian Cancer | phase-1 | — | Source → |
| Pegylated Liposomal Doxorubicin and Immunotherapy in Recurrent Ovarian Cancer | Ovarian Cancer | phase-2 | — | Source → |
| Testing Atezolizumab and Bevacizumab in Rare Solid Tumors | Lung Cancer | phase-2 | — | Source → |
| Ovarian Cancer Treatment Trial: Pembrolizumab and Paclitaxel Combination | Ovarian Cancer | phase-3 | — | Source → |
| Cannabidiol and Bevacizumab Combo Tested | Lung Cancer | lab-study | The apoptotic rate was 15.23% ± 0.42 following cannabidiol treatment and 21.97% ± 0.50 following bevacizumab treatment, and combined treatment significantly increased apoptosis to 50.47% ± 0.67 (< 0.001). | Source → |
| Combination Therapy Extends Survival in Colorectal Cancer Patients | Colorectal Cancer | phase-3 | The median overall survival was 8.9 months for FTD-TPI+bev and 5.8 months for FTD-TPI (P<0.001). | Source → |
| US Doctors' Choices for Treating Advanced Colorectal Cancer | Colorectal Cancer | observational | — | Source → |
| Researchers Identify New Pathway Behind Bevacizumab Resistance in Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| Bevacizumab Not Cost-Effective for Some Colorectal Cancer Patients | Colorectal Cancer | phase-3 | — | Source → |
| Long-Term Survival in Advanced Lung Cancer Patients | Lung Cancer | observational | — | Source → |
| Niraparib May Offer Better Progression-Free Survival for Ovarian Cancer Patients | Ovarian Cancer | observational | The median progression-free survival was 13.77 months in the bevacizumab group. | Source → |
| Bevacizumab's Effectiveness in Ovarian Cancer Treatment | Ovarian Cancer | phase-3 | — | Source → |
| Cost-Effectiveness of Lung Cancer Treatment Questioned | Lung Cancer | phase-3 | Nivolumab plus bevacizumab and chemotherapy yielded an additional 0.90 QALYs with the marginal cost of $231,948.33. | Source → |
| ERBB2-amplified colorectal cancer patients have poorer outcomes with current treatments | Colorectal Cancer | observational | Median progression-free survival was 7.6 months for ERBB2 amp+ patients compared to 8.7 months for ERBB2 amp- patients. | Source → |
| Combining Atezolizumab with Bevacizumab and Chemotherapy for Recurrent Ovarian Cancer | Ovarian Cancer | phase-3 | The hazard ratio for overall survival was 0.83 (95% CI, 0.68 to 1.01; p = .06; median 14.2 months with atezolizumab and 13.0 months with placebo) | Source → |
| Bevacizumab May Reduce Lung Inflammation in Cancer Patients | Lung Cancer | observational | — | Source → |
| Ovarian Cancer Patients on PARP Inhibitors May Face Blood Clot Risk | Ovarian Cancer | observational | Combined treatment with bevacizumab was significantly associated with a decreased risk of thrombosis (OR: 0.262; 95% CI: 0.095-0.724; p = 0.010). | Source → |
| Comparing Bevacizumab Doses in Ovarian Cancer Treatment | Ovarian Cancer | phase-3 | — | Source → |
| USP7's role in ovarian cancer resistance to bevacizumab | Ovarian Cancer | lab-study | — | Source → |
| Bevacizumab's Effect on Ovarian Cancer Treatment | Ovarian Cancer | observational | Among patients with high-risk prognostic factors, median real-world time to next treatment was significantly longer with 1L chemotherapy plus bevacizumab (13.6 [12.7-15.9] months) than chemotherapy alone (11.7 [10.6-12.6] months; p = .032). | Source → |
| Bevacizumab's Role in Treating Advanced Ovarian Cancer | Ovarian Cancer | review | — | Source → |
| Bevacizumab May Help Ovarian Cancer Patients Who Can't Have Surgery | Ovarian Cancer | observational | Median overall survival for unresectable patients showed no significant difference, but bevacizumab significantly improved OS in the CPB group (not reached vs.18 months, p = 0.015) | Source → |
| Biosimilar CT-P16 Shows Equivalent Efficacy in Lung Cancer Treatment | Lung Cancer | phase-3 | Objective response rates were 45.6% and 46.1% for CT-P16 and EU-bevacizumab, respectively. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.